Creatine After 50

After 50, creatine gets pitched as a fix for three separate worries: losing muscle, thinning bones and a slipping memory. Maybe a friend swears by it, or your gym stocks it by the register. That’s a lot of jobs for one scoop of white powder. For Humanic Blue, the useful way to examine creatine after 50 is to separate those claims, because the evidence behind each is very different.

Here’s where the trials land. For muscle, the newest pooled analysis in adults 60 and older finds a small extra strength benefit when creatine accompanies resistance training; added muscle mass and physical-function benefits remain uncertain. A postmenopausal-women analysis found small lean-mass and strength gains, mainly in higher-dose trials paired with training. For bone, two separate two-year trials found no improvement in bone density, although one reported favorable hip-geometry measures with exercise. For the brain, pooled trials suggest possible memory benefits, but age-subgroup findings conflict and controlled dementia trials do not exist. For kidneys, creatine can raise creatinine, a blood marker used to estimate kidney filtration. The estimated filtration rate (eGFR) can therefore fall without a decline in directly measured filtration; supplement use is relevant information for the clinician interpreting the test. No trial shows creatine helps people live longer.

We took the four questions in turn, the way you’d work through them with a friend at the kitchen table.

Question 1: Will it help me keep muscle?

This is the best-studied question, and it’s covered in depth in Does Creatine Help You Live Longer?. A 2026 meta-analysis of 11 randomized trials in generally healthy adults 60 and older found a small additional strength benefit from creatine plus resistance training, rated moderate-certainty evidence. The pooled effects on muscle mass and physical function were not statistically clear and were rated low or very low certainty. The authors cautioned against extending the result to adults who are frail, have substantial age-related muscle loss or have difficulty with everyday physical tasks.

A separate 2026 meta-analysis in postmenopausal women combined seven trials. Across five studies, creatine added 0.37 kg of lean mass (body tissue other than fat) on average; across three smaller studies it added 7.5 kg to the maximum weight women could press once on a leg-press machine. Benefits appeared mainly in trials using at least 5 g daily with resistance training, but that dose subgroup was exploratory and the review was not prospectively registered.

The key word is alongside. A two-year trial in São Paulo gave postmenopausal women with low bone mass either 3 grams of creatine a day or placebo, with no structured training program. Lean mass rose in both groups over time, but creatine added nothing. The authors concluded that the results refute the long-lasting notion that creatine on its own is osteogenic (bone-building) or anabolic (muscle-building) in the long run.

Taken together, these trials found a modest extra strength gain when creatine was added to training. They do not establish that creatine alone can reproduce the effects of training, and its added effect on muscle mass after 60 is not settled.

Question 2: Will it protect my bones?

Two long trials tested this directly in postmenopausal women.

The Brazilian trial tested a modest daily dose without a training program. The Canadian trial paired a higher dose with resistance training three days a week and regular walking. Neither improved bone density. The exercise trial did report better hip-geometry measures and faster walking, but not added strength. See the trials side by side

In the Canadian trial, led by Philip Chilibeck and Darren Candow at the Universities of Saskatchewan and Regina, creatine affected two measures derived from bone images: section modulus, which estimates resistance to bending, and buckling ratio, which relates to structural stability. Both describe the femoral neck, the narrow part of the thighbone near the hip. Bone density did not improve. Whether those secondary geometry changes prevent hip fractures would require a larger and longer trial.

Candow reports industry ties. According to the paper’s disclosures, he has conducted industry-sponsored creatine research, received creatine donations and travel support, serves on the scientific advisory board of AlzChem, which manufactures creatine, and has served as an expert witness in legal cases involving creatine. The trial itself was funded by the Canadian Institutes of Health Research and the Canada Foundation for Innovation.

The bone picture, then: no density benefit in either trial, a possible structural benefit when combined with exercise, and no established fracture reduction.

How do the bone trials change the scope of the claims made for creatine after 50?

Question 3: Will it help my memory?

Muscles, it turns out, aren’t creatine’s only customers. Creatine is also used by the brain for energy, which is why it’s studied for cognition.

A 2024 meta-analysis in Frontiers in Nutrition pooled 16 randomized trials in adults aged about 21 to 76. It reported a small memory benefit, plus signals for attention time and processing speed, but not overall cognition or executive function (skills such as planning and switching between tasks); most outcomes were rated low certainty. Its subgroup analysis favored adults 18 to 60. A 2022 memory-specific meta-analysis reached the opposite age pattern, finding its larger signal in adults 66 to 76, with substantial differences between the studies. Subgroup findings this inconsistent should not be treated as proof of who benefits.

An earlier 2018 systematic review of six trials reached a similar place. Its authors wrote that creatine may improve short-term memory and intelligence or reasoning in healthy people, that its effect on other areas of thinking is still unclear, and that it should be tested in people with dementia or cognitive impairment.

That testing is at an early stage. The pilot results published in 2025 describe people with Alzheimer’s disease who received 20 g daily for eight weeks, with no placebo group. Most took the supplement as required; brain total creatine increased 11%, and several cognitive scores improved from baseline. Without a control group, those changes cannot show treatment efficacy, exclude improvements from repeating the tests or establish dementia prevention. A 2026 scoping review found no controlled human trial in dementia.

Which differences between the cognition trials matter before applying their findings broadly?

Question 4: What about my kidney tests?

This one never makes it onto the tub, but it may be the most practical of the four questions, because kidney function is part of routine blood work.

Creatine is partly converted to creatinine, the waste product most labs use to estimate kidney function (eGFR). A 2026 meta-analysis of 26 randomized trials found that creatine modestly raised blood creatinine and lowered the filtration rate estimated from that marker. But directly measured filtration did not differ significantly, nor did blood urea or protein in the urine, other kidney-related measurements. The substantial variation between studies and the limited duration of most trials mean the result should not be read as proof of long-term safety in every kidney condition.

Creatinine has known non-kidney influences. MedlinePlus lists muscle mass, diet, age and activity among factors that complicate interpretation. The National Institute of Diabetes and Digestive and Kidney Diseases says an equation combining creatinine and cystatin C, another blood protein used to estimate kidney function, is preferred when both markers are available because it is more accurate than creatinine alone.

So if you take creatine and your eGFR looks low, tell your clinician about the supplement and ask whether a cystatin C test makes sense. People who already have kidney disease should discuss creatine before starting it.